The role of PET [18F]FDOPA in evaluating low-grade glioma

Veronica Villani, Carmine M. Carapella, Agostino Chiaravalloti, Irene Terrenato, Francesca Piludu, Antonello Vidiri, Orazio Schillaci, Roberto Floris, Simona Marzi, Alessandra Fabi, Andrea Pace

Research output: Contribution to journalArticlepeer-review


Aim: The aim of the present study was to evaluate the prognostic value of 3,4-dihydroxy-6-[18F]- fluoro-L-phenylalanine ([18F]-FDOPA) positron-emission tomography (PET) in predicting the risk of radiological progression of disease in patients affected by low-grade glioma. Patients and Methods: Patients affected by grade II glioma were consecutively enrolled in a prospective observational study at the Department of Neurology of Regina Elena National Cancer Institute in Rome, Italy. At enrolment, all patients underwent PET [18F]-FDOPA and Magnetic Resonance Imaging (MRI), and clinical and radiological assessments with MRI every six months to evaluate the progression of disease. Results: A total of 50 patients affected by grade II glioma (30 males and 20 females) were included in the study. The multivariate analysis showed that standardized uptake value greater than 1.75 and disease duration were independent predictors of disease progression. Conclusion: These findings suggest that the PET [18F]-FDOPA may play an important prognostic role in evaluation of low-grade glioma.

Original languageEnglish
Pages (from-to)5117-5122
Number of pages6
JournalAnticancer Research
Issue number9
Publication statusPublished - Sep 1 2015


  • Low-grade glioma
  • PET <sup>18</sup>F-FDOPA
  • Prognostic factors
  • Progressive disease

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'The role of PET [18F]FDOPA in evaluating low-grade glioma'. Together they form a unique fingerprint.

Cite this